Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years

Ito, Kazuya; Mugitani, Ayumi; Irie, Shin; Ishibashi, Masayoshi; Takasaki, Yoshio; Shindo, Shizuo; Yokoyama, Takashi; Yamashita, Yuji; Shibao, Keigo; Koyanagi, H; Fukushima, Wakaba; Ohfuji, Satoko; Maeda, Akiko; Kase, Tetsuo; Hirota, Yoshio

doi:10.1097/md.0000000000011551

Cited by 8 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, the VE for children 6 to 11 months old was shown to be the highest among all age groups, although the VE in this age group has not been statistically significant in our previous studies. It is generally thought that, in children 6 to 11 months old, the VE may be lower than in older groups because the vaccine-induced antibody response is immature [ 22 ]. However, it was reported that the VE of two doses of trivalent IIV in subjects 6 months to <1 year old for the 2002/03 to 2007/08 seasons was the highest among all age groups [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

et al. 2021

View full text Add to dashboard Cite

During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months–15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%–46%) and 74% (95% CI, 39%–89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%–77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.

show abstract

Section: Discussionmentioning

confidence: 99%

Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

et al. 2021

View full text Add to dashboard Cite

show abstract

“…nach antineoplastischer Therapie zwei Impfstoffdosen im Abstand von 4 Wochen erhalten. Diese Empfehlung gründet sich auf Studien, in denen gezeigt werden konnte, dass Kinder bei erstmaliger Influenzaimpfung ein schlechteres Ansprechen auf eine Impfstoffdosis aufweisen als nach 2 Impfstoffdosen [7,144,292]. Kinder ab dem Alter von 9 Jahren benötigen in der Regel nur 1 Impfstoffdosis (siehe Fachinformation).…”

Section: Influenza Unter Bzw Nach Antineoplastischer Therapieunclassified

“…Ähnlich wie bei gesunden Kindern <9 Jahren [7,144,292] ist auch bei Erwachsenen nach allogener SZT die Immunogenität nach Gabe einer einzelnen Influenzaimpfstoffdosis vermindert [3]. Daher sollten altersunabhängig bei der ersten Influenzaimpfung nach allogener SZT 2 Dosen eines Influenzatotimpfstoffs gemäss aktueller STIKO-Empfehlung im Abstand von 4 Wochen gegeben werden [74].…”

Section: Influenzaunclassified

Impfen bei Immundefizienz

Laws

Baumann

Bogdan

et al. 2020

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…However, B (Victoria) strain showed higher seroprotection rate and the GMT in the unprimed group. It is well-known that the primed children by previous vaccinations or natural influenza infection have better antibody response to the next influenza immunization 112425. This discordance may be caused by number of shots against Victoria.…”

Section: Discussionmentioning

confidence: 99%

“…This discordance may be caused by number of shots against Victoria. Ito et al24 suggested that one B lineage could not prime the immune response to other B lineages. The antigenic difference between the two B lineage strains suggested that antibodies against the two lineages were monospecific and showed little heterotypic reactivity 26.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months

et al. 2019

View full text Add to dashboard Cite

Background: The titer of influenza vaccine-induced antibodies declines over time, and younger children have lower immunogenicity and shorter duration of immunity. This study aimed to compare persistence of antibody at 6 months after influenza vaccination according to influenza virus strains, vaccine type, antigen dose, and primed status in children aged 6 to 35 months. Methods: A total 124 healthy children aged 6 to 35 months were enrolled from September to December 2016 at 10 hospitals in Korea and randomly assigned to either a full dose of quadrivalent influenza vaccine or a half dose of trivalent influenza vaccine with Victoria B strain group. Hemagglutination inhibition antibody titers (that measure the seroprotection rates) were assessed for the recommended influenza strains at 6 months post vaccination. Results: The seroprotection rates at 6 months for strains A (H1N1), A (H3N2), B/Yamagata, and B/Victoria were 88.7%, 97.4%, 36.6%, and 27.6%, respectively. The seroprotection rates for A (H1N1), A (H3N2) and B (Victoria) were 91.4%, 98.7% and 27.5% in a full dose of quadrivalent vaccine vs. 83.7%, 94.6% and 27.9% in a half dose trivalent vaccine, respectively. The seroprotection rate for the B (Yamagata) strain was 23.8% in the quadrivalent group and 14.0% in the trivalent group. Conclusion: Persistence of antibodies at 6 months was more favorable against the influenza A strains than against the B strains. Persistence of antibodies to additional B strain at 6 months was superior in the quadrivalent vaccine group. The immunity of primed children with different B strains was not superior to that of the unprimed group with another B strain.

show abstract

Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years

Abstract: Supplemental Digital Content is available in the text

Cited by 8 publications

References 19 publications

Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

Influenza vaccine effectiveness against influenza A in children based on the results of various rapid influenza tests in the 2018/19 season

Impfen bei Immundefizienz

Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6–35 Months

Contact Info

Product

Resources

About